갑상선암에서 표적치료항암제의 피부 관련 부작용
Skin-Related Toxicity of Tyrosine Kinase Inhibitor in Thyroid Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality of life and therapeutic effectiveness, it is essential to cope with a variety of severity of skin-related toxicity induced by MTKI. Herein, we will discuss two representative cases of skin-related toxicities which were managed by discontinuation/ reduction of therapeutic doses of MTKI and were treated by proper medication in thyroid cancer patients with distant metastasis.
Abstract
Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality of life and therapeutic effectiveness, it is essential to cope with a variety of severity of skin-related toxicity induced by MTKI. Herein, we will discuss two representative cases of skin-related toxicities which were managed by discontinuation/ reduction of therapeutic doses of MTKI and were treated by proper medication in thyroid cancer patients with distant metastasis.
참고문헌 (9)
- Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
- Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
- Chanprapaph K, "Multikinase inhibitor-induced hand-foot skin reaction: A review of clinical presentation, pathogenesis, and management", Am J Clin Dermatol, 17(4), pp.387~402 (2016)
- Resteghini C, "Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients", Best Pract Res Clin Endocrinol Metab, 31(3), pp.349~361 (2017)
- Jean GW, "Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers", JAMA Oncol, 2(4), pp.529~534 (2016)
- Erber R, "Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms", FASEB J, 18(2), pp.338~340 (2004)
- Jain L, "Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction", Pharmacotherapy, 30(1), pp.52~56 (2010)
- Brose MS, "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial", Lancet Oncol, 17(9), pp.1272~1282 (2016)
- Brose MS, "Management of sorafenib-related adverse events: a clinician's perspective", Semin Oncol, 41(Suppl 2), pp.S1~S16 (2014)